Drug Approval | June 23, 2026
Teva submits FDA application for experimental Tourette syndrome treatment ecopipam
The filing is backed by positive Phase 3 results recently published in JAMA Neurology
The filing is backed by positive Phase 3 results recently published in JAMA Neurology
After a volatile decade in which approvals swung sharply from year to year, 2025’s total pushed past long-term norms, exceeding the 10-year average
The safety profile of the Lunsumio and Polivy combination was consistent with the known profiles of the individual study medicines
The move comes as demand rises for wider access to glaucoma screening and more flexible clinical workflows
As per the company’s Restated H1 2025 Financials, its continuing business delivered CORE EBITDA of CHF 922 million, representing a margin of 30.4%
Advanced comprehensive oncology centre was inaugurated by the legendary former Indian cricketer VVS Laxman
Initiative seeks innovative experimental and computational approaches to uncover neural circuits regulating immune function and identify novel therapeutic targets
The company plans an aggressive partnering push, with 62 pre-scheduled meetings over four days, focused on out-licensing, co-development, and strategic collaborations with global pharmaceutical and biotech players
Bolstering neuroscience push with late-stage Tourette therapy
The FDA has granted Priority Review, setting a target decision date of 9 October 2026, potentially accelerating access to a new treatment option for a subset of patients with high-risk colon cancer characterized
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
